The top executives of Moderna, Akamai, and FMC just bought stock on the open market. All three shares are in the red for 2025 ...

Moderna stock has surged more than 20% this week after regulatory filings showed several executives bought shares on the open ...

Shares of the American pharmaceutical company Moderna (MRNA) climbed over 8% in pre-market trading following strategic ...

Despite high R&D spending and cash burn, Moderna aims for breakeven by 2028, driven by new vaccine opportunities. Explore ...

In a couple of regulatory filings with the SEC, it was revealed that Moderna’s CEO Stephane Bancel and director Paul Sagan acquired common stock worth $6 million. On Monday, Bancel acquired ...

Moderna's CEO Buys MRNA Stock Last night, two purchases of Moderna's stock by a firm controlled by MRNA CEO Stephane Bancel were reported. Bancel's company, called Boston Biotech Ventures ...

Moderna shares experienced a significant surge in trading on Thursday, posting a 5.58% gain in European markets and an impressive jump of up to 16% on the NASDAQ. This remarkable performance was ...

And the company isn't done. CEO Stéphane Bancel says that the goal is to eliminate close to $1 billion in costs by the end of ...

Moderna (MRNA) stock is climbing 8% after the drug maker won a key court case and its CEO bought shares on the open market.